source
- Structure’s obesity portfolio impresses on GLP-1 and amylin fronts in dual data dropStructure Therapeutics’ oral GLP-1 candidate aleniglipron showed 72-week efficacy “in line” with Novo Nordisk’s oral Wegovy, BMO Capital Markets wrote in a note to investors. Meanwhile, Structure’s…BioSpace · 46m ago↗ source
- Menarini to launch Gan & Lee’s GLP-1 drug bofanglutide across Europe in $771 M partnershipItalian firm Menarini Group has entered a licensing agreement with Chinese insulin producer Gan & Lee Pharmaceuticals to bring the GLP-1 compound bofanglutide to Europe. The deal includes an upfro…